Navigation Links
Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine
Date:9/21/2011

BROOMFIELD, Colo., Sept. 21, 2011 /PRNewswire/ -- Ariel Pharmaceuticals, Inc., a private, specialty pharmaceutical company focused on the development and commercialization of products for acute central nervous system (CNS) diseases and trauma, announced today that it has in-licensed its lead product, AP-1531, for the treatment of acute migraine attacks, from the specialist healthcare company BTG International Ltd (LSE: BGC).

While the precise cause of migraines is not fully understood, changes in vascular tone and inflammatory processes appear to be key contributing factors.  Prostaglandins are naturally existing molecules that are integral components of both vascular and inflammatory reactions in the central and peripheral nervous systems.   There is evidence to demonstrate that prostaglandin E2 (PGE2) binding to the EP4 receptor causes dilation of small blood vessels in the brain, while leaving coronary and pulmonary arteries unaffected, and can stimulate a variety of inflammatory mechanisms.  AP-1531 is a potent and selective EP4 receptor antagonist that specifically targets PGE2-EP4 binding which may treat migraines. AP-1531 has shown promising results  in several disease models of migraine and acute pain and inflammation.  

"We are extremely pleased with the data from six Phase I studies on AP-1531 and are confident this approach will yield positive results as we initiate a Phase 2 study in migraine patients in 2012," said Steve Orndorff, President and CEO of Ariel Pharmaceuticals.  "Given that the current standard of care for moderate to severe migraines can take up to 90 minutes to provide relief and works temporarily or not at all in many patients, in addition to having potentially serious side effects, we're committed to developing a safer and more efficacious alternative that will provide better quality care to patients.  We believe AP-1531 will validate our business model of in-licensing clinic-ready dru
'/>"/>

SOURCE Ariel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ariel Ways GovBuys Awarded VA Contract
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
7. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... The acute coronary syndrome (ACS) therapeutics market ... of generics. While generic ACS drugs currently lead in ... to increase to more than 60 percent of the ... novel pipeline products between 2015 and 2019. The US ... of revenues, driven primarily by incidence rates of ACS ...
(Date:9/1/2015)... 1, 2015  Amgen (NASDAQ: AMGN ) ... the areas of Alzheimer,s disease and migraine. The ... by teaming up with Novartis on a differentiated ... genetically predisposed individuals at risk of developing Alzheimer,s ... the commercialization of its migraine programs in the ...
(Date:9/1/2015)... 1, 2015 Ardelyx, Inc. (NASDAQ: ... gastrointestinal and cardio-renal diseases, today announced that Sanofi ... and license agreement for Ardelyx,s portfolio of NaP2b ... payment associated with termination and the return of ... Sanofi entered into an option and license agreement ...
Breaking Medicine Technology:Branded Acute Coronary Syndrome Therapies to Grab Market Share from Generic Drugs Globally 2Branded Acute Coronary Syndrome Therapies to Grab Market Share from Generic Drugs Globally 3Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 2Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 3Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 4Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 5Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 6Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 7Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 8Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 9Ardelyx Regains NaP2b Program from Sanofi 2Ardelyx Regains NaP2b Program from Sanofi 3
... 25, 2007 - CytRx Corporation,(NASDAQ:CYTR), a biopharmaceutical ... human therapeutics, today,reported safety and tolerability results ... dose,clinical trial in healthy volunteers with its ... of this trial support,the use of arimoclomol ...
... Reported Unlike What Is Commonly Seen In,Insulin Therapy, ... announced results of a new study that further ... detemir,[rDNA origin] injection). Patients with type 2 diabetes ... and achieve improvements,in blood sugar, comparable to dosing ...
Cached Medicine Technology:CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 2CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 3CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 4CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 5New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 2New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 3New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 4New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 5
(Date:9/2/2015)... IL (PRWEB) , ... September 02, 2015 , ... ... off ahead of Breast Cancer Awareness Month (BCAM), Bright Pink, a national non-profit ... young women, will launch Act On Facts, a campaign to educate women to ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... hundreds of thousands of plastic surgeries conducted each year on teenagers, quoting a ... the growing numbers. Beverly Hills-based plastic surgeon Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., known ...
(Date:9/1/2015)... ... September 01, 2015 , ... The Capillus82™ ... treatment of androgenic alopecia in adults, announces Miami-based medical device manufacturer, Capillus, LLC. ... also demonstrating its safety when used at home to combat hair loss. ...
(Date:9/1/2015)... ... 01, 2015 , ... ProRehab Physical Therapy , Louisville’s ... with Apex Physical Therapy (Apex) is official as of August 26, ... and empathetic care to local residents from their combined eight locations throughout Louisville. ...
(Date:9/1/2015)... ... September 01, 2015 , ... From Aug. 17-21, Calvary Hospital ... from ages 6-18. Calvary’s Camp Compass® has taken place at Kingsborough Community College in ... counselors, some of whom work for Calvary, and two junior counselors who were campers ...
Breaking Medicine News(10 mins):Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 3Health News:Teen Plastic Surgery Article Understates the Most Important Realities of Procedures on Young People, Notes Dr. J 2Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3
... Fla. Like rock stars of the rodent world, the ... most attention from the ladies, a University of Florida study ... vocal trills, and a bravura performance attracts more interest from ... the journal Animal Behaviour by doctoral candidate Bret ...
... area known for its high concentration of asbestos-contaminated dust, have ... regions where asbestos pollution levels are lower. This has been ... Ben-Shlomo and Dr. Uri Shanas of the University of Haifa,s ... there is a link between the higher levels of asbestos ...
... research project that develops objective and efficient methods ... requires a holistic view of the patient combining ... imaging and blood samples. "The aim ... objective indicator to diagnose Alzheimer,s disease at the ...
... Reinberg HealthDay Reporter , TUESDAY, June 14 (HealthDay ... it will require new labeling for sunscreens to identify products ... early skin aging and helping to prevent sunburn. ... A rays (UVA) and ultraviolet B (UVB) rays can be ...
... Ever since the Institute of Medicine issued its landmark report ... paid to improving patient safety in hospitals nationwide. However, ... even death, occur in private physician offices and outpatient clinics ... its kind -- researchers at Weill Cornell Medical College found ...
... the countryside, where open space is plentiful and there ... a million rural elders are far more likely to ... than their suburban counterparts, according to a new policy ... All three conditions are risk factors ...
Cached Medicine News:Health News:UF study: When singing mice choose a mate, a skillful song gets the gal 2Health News:UF study: When singing mice choose a mate, a skillful song gets the gal 3Health News:Genetic mutation linked to asbestos exposure 2Health News:Several methods for early diagnosis of Alzheimer's disease developed by European scientists 2Health News:Several methods for early diagnosis of Alzheimer's disease developed by European scientists 3Health News:Several methods for early diagnosis of Alzheimer's disease developed by European scientists 4Health News:FDA Issues New Rules on Sunscreens 2Health News:FDA Issues New Rules on Sunscreens 3Health News:JAMA study points to patient safety risks outside hospital walls 2Health News:JAMA study points to patient safety risks outside hospital walls 3Health News:Out of reach? Rural elders have highest rates of obesity, diabetes, heart disease 2
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
Medicine Products: